Immunophenotype of ovarian cancer as predictor of clinical outcome: Evaluation at primary surgery and second-look procedure

Gynecologic Oncology

Volumn 70, Issue 3, 1998, Pages 378-385

  Goff, Barbara A ^a   Ries, Justin A ^a   Els, Lisa P ^a   Coltrera, Marc D ^a   Gown, Allen M ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; GLYCOPROTEIN P; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; STEROID RECEPTOR; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; ONCOGENE C ERB; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SECOND LOOK SURGERY; TUMOR SUPPRESSOR GENE;

EID: 0031660241     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5094     Document Type: Article

References (36)

1. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper J T, Dodge R, Clarke-Pearson D L, Marks, P, McKenzie S, Yin S, Bast R C Jr. Overexpression of HER-2/neu. Cancer Res. 50:1990;4087-4091.
2. Felipe E, Del-Campo J M, Rubio D, Vidal M T, Colomer R, Bermejo B. Overexpression of c-erb. Cancer. 75:1995;2147-2152.
3. Rubin S C, Finstad C L, Wong G Y, Almadrones L, Plante M, Lloyd K O. Prognostic significance of HER-2/neu. Am J Obstet Gynecol. 168:1993;162-169.
4. Fajac A, Benard J, Lhomme, Rey A, Duvillard P, Richard F, Bernaudin J F, Riou G. C-erb. Int J Cancer. 64:1995;146-151.
5. Gadducci A, Ciancia E M, Campani D, Malagnino G, DeLuca F, Facchini V, Pingitore R, Fioretti P. Immunohistochemical detection of p185 product, p21 product, and proliferating cell nuclear antigen (PCNA) in formalin-fixed paraffin-embedded tissues from ovarian carcinomas. Preliminary data. Eur J Gynaecol Oncol. 15:1994;359-368.
6. Singleton, TP, Perrone T, Oakley G, Niehans G A, Carson L, Cha S S, Strickler J G. Activation of c-erb. Cancer. 73:1994;1460-1466.
7. Seidman J D, Frisman D M, Norris H J. Expression of the HER-2/neu. Cancer. 70:1992;2857-2860.
8. Porter P L, Gown A M, Kramp S G, Coltrera M D. Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue. Am J Pathol. 140:1992;145-153.
9. Diebold J, Baretton G, Felchner M, Meier W, Dopfer K, Schmidt M, Lohrs U. bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol. 105:1996;341-349.
10. Henriksen R, Strang P, Wilander E, Backstrom T, Tribukait B, Oberg K. p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol. 53:1994;301-306.
11. Klemi P J, Pylkkanen L, Kiilholma P, Kurvinen K, Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer. 76:1995;1021-1208.
12. Levesque M A, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, Diamandis E P. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer. 75:1995;1327-1338.
13. Hartmann L C, Podratz K C, Keeney G L, Kamel N A, Edmonson J H, Grill J P, Su J Q, Katzmann J A, Roche P C. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol. 12:1994;64-69.
14. Kohler M F, Kerns B J, Humphrey P A, Mark J R, Bast R C Jr, Berchuck A. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol. 81:1993;643-650.
15. Niwa K, Itoh M, Murase T, Morishita S, Itoh N, Mori H, Tamaya T. Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance. Br J Cancer. 70:1994;1191-1197.
16. Reles A, Schmider A, Press M F, Schonborn I, Friedmann W, Huber-Schumacher S, Lichtenegger W. Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome. J Cancer Res Clin Oncol. 122:1996;489-494.
17. Isola J, Kallioniemi O P, Korte J M, Wahlstrom T, Aine R, Helle M, Helin H. Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival. J Pathol. 162:1990;295-301.
18. Kerns B J, Jordan P A, Faerman L L, Berchuck A, Bast R C Jr, Layfield L J. Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol. 101:1994;192-197.
19. Meden H, Marx D, Raab T, Kron M, Schauer A, Kuhn W. EGFR and overexpression of the oncogene c-erb. J Obstet Gynaecol. 21:1995;167-178.
20. Naylor M S, Malik S T, Stamp G W, Jobling T, Balkwill F R. In situ detection of tumour necrosis factor in human ovarian cancer specimens. Eur J Cancer. 26:1990;1027-1030.
21. Veneroni S, Zaffaroni N, Daidone M G, Benini E, Villa R, Silvestrini R. Expression ofp. Eur J Cancer. 7:1994;1002-1007.
22. Germain I, Tetu B, Brisson J, Mondor M, Cherian M G. Markers of chemoresistance in ovarian carcinomas: an immunohistochemical study of 86 cases. Int J Gynecol Pathol. 15:1996;54-62.
23. Geisler J P, Wiemann M C, Miller G A, Zhou Z, Geisler H E. Change in MIB-1 staining between primary and recurrent epithelial ovarian cancer. Eur J Gynaecol Oncol. 16:1995;353-355.
24. Gown A M, de Wever N, Battifor H. Microwave-based antigenic unmasking: a revolutionary new technique for routine immunohistochemistry. Appl Immunohistochem. 1:1993;256-266.
25. Gown A M, Vogel A M. Monoclonal antibodies to human intermediate filament proteins. II. Distribution of filament proteins in normal human tissues. Am J Pathol. 114:1984;309-321.
26. Veronese S M, Maisano C, Scibilia J. Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer. Anticancer Res. 15:1995;2717-2722.
27. DiLeo A, Bajetta E, Bignazoli L, Bohm S, Mariani L, Menard S, Pilotti S, Fabbiani M, Gebbi V, Oriana S. An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis. Eur J Cancer. 31A:1995;2248-2254.
28. Garzetti G G, Ciavattini A, Lucarini G, Goteri G, DeNictolis M, Romanini C, Biagnini G. Modulation of expression of p53 and cell proliferation in locally advanced cervical carcinoma after neoadjuvant combination chemotherapy. Eur J Obstet Gynecol. 63:1995;31-36.
29. Eliopoulos A G, Kerr D J, Herod J, Hodgkins L, Krajewski S, Reed J C, Young L S. The control of apoptoses and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene. 11:1995;1217-1228.
30. Herod J J, Eliopoulos A G, Warwick J, Niedobitek G, Young L S, Kerr D J. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res. 56:1996;2178-2184.
31. Vasey P A, Jones N A, Jenkins S, Dive C, Brown R. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmcol. 50:1996;1536-1540.
32. Righetti S C, Della Torre G, Pilotti S, M'enard S, Ottone F, Colnaghi M I, Pierotti M A, Lavarino C, Cornarotti M, Oriana S, Bohm S, Bresciani G L, Spatti G, Zunino F. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 56:1996;689-693.
33. Buttitatta F, Marchetti A, Gadducci A, Pellegrini S, Morganti M, Carnicelli V, Cosio S, Gagetti O, Genazzani A R, Vevilacqua G. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer. 75:1997;230-235.
34. Arao S, Suwa H, Mandai M, Tashiro H, Miyazaki K, Okamura H, Nomura H, Hiai H, Fukumoto M. Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer. Cancer Res. 54:1994;1355-1359.
35. Codegoni A M, Broggini M, Pitelli M R, Pantarotto M, Torri V, Mangioni C, D'Incalci M. Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Gynecol Oncol. 65:1997;130-137.
36. Izquierdo M A, van der Zee A G, Vermorken J B, van der Valk P, Belien J A, Giaccone G, Scheffer G L, Flens M J, Pinedo H M, Henemans P. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst. 87:1995;1230-1237.